Skip to content
10-K

Annual Report

Moleculin Biotech, Inc. MBRX

0001437749-26-008841

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $13K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$22.74M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$23.86M
Cash And Equivalents FY 2025 · Dec 31, 2025 $8.88M
Cash And Equivalents FY 2025 · Dec 31, 2024 $4.28M
Stockholders Equity FY 2025 · Dec 31, 2025 $15.01M
Stockholders Equity restated FY 2025 · Dec 31, 2024 $11.21M
Stockholders Equity restated FY 2025 · Dec 31, 2023 $30.93M
Current Liabilities FY 2025 · Dec 31, 2025 $6.85M
Current Liabilities FY 2025 · Dec 31, 2024 $5.36M
Total Liabilities FY 2025 · Dec 31, 2025 $7.12M
Total Liabilities restated FY 2025 · Dec 31, 2024 $5.72M
Current Assets FY 2025 · Dec 31, 2025 $9.69M
Current Assets FY 2025 · Dec 31, 2024 $5.19M
Total Assets FY 2025 · Dec 31, 2025 $22.13M
Total Assets FY 2025 · Dec 31, 2024 $16.93M
Eps Basic FY 2025 · Dec 31, 2025 −$28.42
Eps Basic restated FY 2025 · Dec 31, 2024 −$189.14
Sga Expense FY 2025 · Dec 31, 2025 $9.12M
Sga Expense FY 2025 · Dec 31, 2024 $8.79M
Rd Expense FY 2025 · Dec 31, 2025 $15.89M
Rd Expense FY 2025 · Dec 31, 2024 $17.73M
Net Income FY 2025 · Dec 31, 2025 −$33.56M
Net Income restated FY 2025 · Dec 31, 2024 −$26.05M
Operating Income FY 2025 · Dec 31, 2025 −$25.1M
Operating Income FY 2025 · Dec 31, 2024 −$26.64M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $0